J&J Opens Houston Incubator With 21 Startups, 12 Biopharma Firms
This article was originally published in Scrip
Executive Summary
Johnson & Johnson Innovation LLC, the big pharma's early-stage company accelerator and partnership negotiator, opened its fifth US incubator to house and support startup firms with 21 tenants, including a dozen therapeutics developers, in the Houston, Texas facility.
You may also be interested in...
BIO 2016 Notebook: Patient Perspectives, Risk-Sharing, Microbiomes and Incubating Success
Scrip's second full day of meetings and events during the annual BIO International Convention delivered diverse insights about including patients in drug development, sharing risk with CROs, microbiome-targeting therapies, and the benefits of incubating early-stage technology.
VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.